Table 5_The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.xlsx

Table 5_The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.xlsx

<p>As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Jingxian Li (2328664) (author)
مؤلفون آخرون: Kun Shan (3520346) (author), Wei Huang (36889) (author), Qiang Su (1611796) (author), Yuanjiong Qi (12001241) (author), Zhihong Zhang (2027) (author), Jianqiang Zhu (1669477) (author), E. Du (3833092) (author)
منشور في: 2025
الموضوعات:
Genetic Immunology
RC48-ADC
MIBC
artesunate
molecular subtypes
targeted therapy
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

مواد مشابهة